HMGB1 as a therapeutic target in disease

• Published in: Journal of cellular physiology Vol. 236; no. 5; pp. 3406 - 3419
• Main Authors: Xue, Jiaming, Suarez, Joelle S., Minaai, Michael, Li, Shuangjing, Gaudino, Giovanni, Pass, Harvey I., Carbone, Michele, Yang, Haining
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2021
• Subjects: Alarmins - metabolism; Animals; antagonist; Antagonists; Chemotaxis; Cytokines; Cytokines - metabolism; Damage patterns; Endotoxemia; Endotoxemia - metabolism; Extracellular matrix; Glycyrrhizin; HMGB1; HMGB1 protein; HMGB1 Protein - metabolism; Homeostasis; Humans; Hypoxia; Inflammation; Inflammation - metabolism; Inflammatory diseases; Ischemia; Isoforms; Leukocytes (granulocytic); Leukocytes (neutrophilic); Macrophages; Macrophages - metabolism; Myeloid cells; Proteins; Pyruvic acid; Reperfusion; targeted therapy; Transcription; targeted therapy; antagonist; HMGB1

High‐mobility group box 1 (HMGB1) was initially recognized as a ubiquitous nuclear protein involved in maintaining the nucleosome integrity and facilitating gene transcription. HMGB1 has since been reevaluated to be a prototypical damage‐associated molecular pattern (DAMP) protein, and together with...